6-keto-PGF1a(6-keto-prostaglandin F1a) ELISA Kit (E-EL-0054)
Add to cart
For research use only.
Product Summary
| Sensitivity | 9.38 pg/mL |
| Detection Range | 15.63-1000 pg/mL |
| Sample Volume | 50 μL |
| Total Assay Time | 2 h 30 min |
| Reactivity | Universal |
| Specificity | This kit recognizes Universal 6-keto-PGF1a in samples.No significant cross-reactivity or interference between Universal 6-keto-PGF1a and analogues was observed |
| Recovery | 80%-120% |
| Sample Type | Serum, plasma and other biological fluids |
| Detection Method | Colorimetric method, ELISA, Competitive |
| Assay Type | Competitive-ELISA |
| Size | 96T / 48T / 24T / 96T*5 / 96T*10 |
| Storage | 2-8℃ |
| Expiration Date | 12 months |
Performance
| Typical data |
The following data was generated by the Quality Control Department, under controlled laboratory conditions (ambient temperature: 18-25 °C, relative humidity: 35-75%) using standardized procedures (TMB reaction at 37 °C in the dark for 15 minutes, followed by termination and OD measurement). These values are provided for reference only.
Actual results may vary due to differences in laboratory conditions, operator technique, and equipment. Users are required to generate a standard curve using their own experimental data.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Precision |
Intra-assay Precision (Within-run Precision): Three samples representing low, mid, and high concentrations of Human IL-6 were tested 20 times on a single plate.
Inter-assay Precision (Between-run Precision): Three samples representing low, mid, and high concentrations of Human IL-6 were tested on three separate plates, with 20 replicates per plate, to assess variability among assays.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Recovery |
The recovery of Universal 6-keto-PGF1a was evaluated by spiking samples at low, mid, and high concentrations across the assay range in various sample matrices.
The assay performance was assessed by comparing the measured concentrations to the expected spiked amounts to determine the percent recovery.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Linearity |
Linearity of the assay was evaluated by spiking samples with high concentrations of Universal 6-keto-PGF1a and performing serial dilutions using Standard & Sample Diluent to produce concentrations spanning the assay's dynamic range.
The measured values were then compared to the expected concentrations to assess the linearity of response.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Stability |
Each kit batch is subjected to accelerated stability testing and real-time stability monitoring. Sample performance is evaluated after storage at 37 °C for 10 days to assess the impact of elevated temperature on assay reliability and reagent integrity.
|
|||||||||||||||||||||||||||||||||||||||||||||
Test Principle
This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Universal 6-keto-PGF1a. During the reaction, Universal 6-keto-PGF1a in the sample or standard competes with a fixed amount of Universal 6-keto-PGF1a on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Universal 6-keto-PGF1a. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Universal 6-keto-PGF1a in tested samples can be calculated by comparing the OD of the samples to the standard curve.
Background
6-keto-PGF1α is a stable hydrolysis product of prostacyclin (PGI2). Due to the short half-life of PGI2 in buffer (2-3 minutes) the production of prostacyclin is typically monitored by measurement of the 6-keto-PGF1α metabolite and its derivative in urine, 2,3-dinor-6-keto-PGF1α. PGI2 has autocoid functions that include platelet aggregation, inhibition of vasoconstrictor responses to pressor hormones, platelet anti- and disaggregatory properties, and reproductive functions. The effects are induced by receptor-mediated elevation of cAMP. Prostacyclin has clinical applications in atherosclerosis and protection from myocardial ischemia.
| Research Area | Cardiovascular |
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.sample_type}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
No files available. Please enter the correct identification code in the search area to query the relevant documents.
| Title | Status | Valid until | Action | |
|---|---|---|---|---|
| {{v.文件名}} | {{v.status_str}} | {{v.timestamp_str}} | Download | / |
*Note：Please download the relevant files within the validity period. After expiration, file preview and download will not be available on the page.
Videos
Resources
Contact with Us
Toll-free: 1-888-852-8623
Tel: 1-832-243-6086
Add:
14780 Memorial Drive, Suite 105,
Houston, Texas, 77079, USA
Houston, Texas, 77079, USA
